drugset

drugset / Trial / NCT03424473

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

NCT03424473 ↗

Expanded access No longer available Seagen Inc.

Summary

Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information ([email protected]).

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tucatinib	Small molecule	—	—

Indications

No indication recorded.